Premium
Model‐Based Comparison of Dose‐Response Profiles of Tofacitinib in Japanese Versus Western Rheumatoid Arthritis Patients
Author(s) -
Suzuki Misaki,
Shoji Satoshi,
Miyoshi So,
Krishnaswami Sriram
Publication year - 2020
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/jcph.1514
Subject(s) - tofacitinib , rheumatoid arthritis , janus kinase inhibitor , medicine , rheumatology , placebo , pharmacology , alternative medicine , pathology
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The aim of this analysis was to characterize the relationship between tofacitinib dose and efficacy, as measured by American College of Rheumatology (ACR) response rates, and to compare this between Japanese and Western patients with RA. Efficacy data were pooled from 2 double‐blind, dose‐ranging phase 2 studies of tofacitinib monotherapy 1‐15 mg twice daily in patients with RA with an inadequate response to disease‐modifying antirheumatic drugs (DMARDs). NCT00550446 was carried out in mostly Western patients and NCT00687193 in Japanese patients. ACR20, ACR50, and ACR70 response rates in week 12 were analyzed using maximum drug effect (E max ) models on the logit domain. Both studies showed a dose‐response for each end point, supporting the efficacy of tofacitinib in patients with inadequate response to DMARDs. Study‐specific differences in E max were noted, whereas potency (dose providing half the maximum effect [ED 50 ]) was similar across studies. After adjustment for study differences in E max by calculating the fractions of the maximum placebo‐adjusted proportion of ACR responses, the estimated locations for the 5‐ and 10‐mg twice‐daily doses on the dose‐response curves were similar for the 2 patient populations: ACR20, ACR50, andACR70 mean fractional responses for 5 and 10 mg twice daily were 0.78, 0.43, 0.32 and 0.90, 0.69, and 0.56, respectively, for the Japanese study and 0.54, 0.41, and 0.22 and 0.73, 0.61, and 0.40, respectively, for the Western study. This analysis therefore supports the rationale for the same dosing regimen in Japanese patients as in Western patients from an efficacy perspective.